• 1
    Poiesz BJ, Ruscetti FW, Reitz MS, Kalyanaraman VS, Gallo RC. Isolation of a new type C retrovirus (HTLV) in primary uncultured cells of a patient with Sezary T-cell leukemia. Nature 1981; 294: 268271.
  • 2
    Kalyanaraman VS, Sarngadharan MG, Robert-Guroff M, Miyoshi I, Golde D, Gallo RC. A new subtype of human T-cell leukemia virus (HTLV-II) associated with a T-cell variant of hairy-cell leukemia. Science 1982; 218: 571573.
  • 3
    Popovic M, Reitz MS, Sarngadharan MG et al. The virus of Japanese adult T-cell leukemia is a member of the human T-cell leukemia virus group. Nature 1982; 300: 6366.
  • 4
    Osame M, Usuku K, Izumo S et al. HTLV-I associated myelopathy, a new clinical entity. Lancet 1986; i: 10311032.
  • 5
    Tokudome S, Tokunaga O, Shimamoto Y et al. Incidence of adult T-cell leukemia/lymphoma among human T-lymphotrophic virus type I carriers in Saga, Japan. Cancer Res 1989; 49: 226228.
  • 6
    Kondo T, Kono H, Miyamoto N et al. Age- and sex-specific cumulative rate and risk of ATLL for HTLV-I carriers. Int J Cancer 1989; 43: 10611064.
  • 7
    Murphy EL, Hanchard B, Figueroa JP et al. Modeling the risk of adult T-cell leukemia/lymphoma in persons infected with human T-lymphotrophic virus type I. Int J Cancer 1989; 43: 250253.
  • 8
    Cleghorn FR, Manns A, Falk Ret al. Effect of human T-lymphotrophic virus type I infection on non-Hodgkin's lymphoma incidence. J Natl Cancer Inst 1995; 87: 10091014.
  • 9
    Maloney EM, Cleghorn FR, Morgan OSC et al. Incidence of HTLV-I-associated myelopathy/tropical spastic paraparesis (HAM/TSP) in Jamaica and Trinidad. J Acquir Immune Defic Syndr 1997; 17: 167170.
  • 10
    Manns A, Hisada M, Grenada LL. Human T-lymphotrophic virus type I infection. Lancet 1999; 353: 19511958.
  • 11
    Goedert JJ, Fung MW, Felton S, Battjes RJ, Engels EA. Cause-specific mortality associated with HIV and HTLV-II infections among injecting drug users in the USA. AIDS 2001; 15: 12951302.DOI: 10.1097/00002030-200107060-00012
  • 12
    Hollsberg P, Hafler DA. Pathogenesis of diseases induced by human lymphotrophic virus type I infection. N Engl J Med 1993; 328: 11731182.
  • 13
    Glynn SA, Kleinman SH, Schreiber GB et al. Trends in the incidence and prevalence of major transfusion-transmissible viral infections in US blood donors, 1991–96. JAMA 2000; 284: 229235.
  • 14
    Levine PH, Dosik H, Joseph EM et al. A study of adult T-cell leukemia/lymphoma incidence in central Brooklyn. Int J Cancer 1999; 80: 662666.
  • 15
    Harrington WJ, Ucar A, Gill P et al. Clinical spectrum of HTLV-I in south Florida. J Acquir Immune Defic Syndr 1995; 8: 466473.
  • 16
    Dosik H, Goldstein MF, Poiesz BJ et al. Seroprevalence of human T-lymphotrophic virus in black from a selected central Brooklyn population. Cancer Invest 1994; 12: 289295.
  • 17
    Murphy EL, Watanabe K, Nass CC et al. Evidence among blood donors for a 30-year-old epidemic of human T lymphotrophic virus type II infection in the United States. J Infect Dis 1999; 180: 17771783.
  • 18
    Perez G, Ortiz-Interian C, Lee H et al. Human immunodeficiency virus and human T-cell leukemia virus type I in patients undergoing maintenance hemodialysis in Miami. Am J Kidney Dis 1989; 14: 3943.
  • 19
    Kleinman SH, Swanson P, Allain JP, Lee H. Transfusion transmission of human T-lymphotrophic virus types I and II. serologic and polymerase chain reaction results in recipients identified through look-back investigations. Transfusion 1993; 31: 1418.
  • 20
    Sullivan MT, Williams AE, Fang CT, Grandinetti T, Poiesz BJ, Ehrlich GD. Transmission of human T-lymphotrophic virus types I and II by blood transfusion. Arch Intern Med 1991; 151: 20432048.
  • 21
    Donegan E, Lee H, Operskalski EA et al. Transfusion transmission of retroviruses: human T-lymphotrophic virus types I and II compared with human immunodeficiency virus type I. Transfusion 1994; 34: 478483.
  • 22
    Remesar MC, Pozo AE, Pittis MG, Mangano AM, Sen L, Briones L. Transmission of HTLV-I by kidney transplant. Transfusion 2000; 40: 14211422.DOI: 10.1046/j.1537-2995.2000.40111421.x
  • 23
    Zaaijer H. Human T-lymphotrophic virus infection: Is it a threat? Transplant Proc 1996; 28: 2940.
  • 24
    Gridelli B, Remuzzi G. Strategies for making more organs available for transplantation. N Engl J Med 2000; 343: 404410.
  • 25
    Claquin J, Romano P, Noury D et al. Human T-lymphotrophic virus 1–2 antibodies in potential organ donors in France. Transplant Proc 1996; 28: 189190.
  • 26
    Claquin J, Romano P, Sellami F, Gassin M. Human T cell lymphotrophic virus 1–2-positive nonretrieved cerebral deaths in France, 1992–94. Transplant Proc 1996; 28: 2953.
  • 27
    Mate G, Gonzalez C, Bronsoms JM, Valles M, Torguet P, Mauri JM. Transplant and organ donor-associated transmission of human T-lymphotrophic virus types I and II. Transplant Proc 1995; 27: 2417.
  • 28
    Domen RE, Nelson KA. Results of a survey of infectious disease testing practices by organ procurement organizations in the United States. Transplantation 1997; 63: 17901794.
  • 29
    Zanke BW, Rush DN, Jeffery JR, Israel LG. HTLV-I T-cell lymphoma in cyclosporine-treated renal transplant patients. Transplantation 1989; 48: 695697.
  • 30
    Tsurumi H, Tani K, Tsuruta T, Shirato R, Matsudaira T, Tojo A et al. Adult T-cell leukemia developing during immunosuppressive treatment in a renal transplant recipient. Am J Hematol 1992; 41: 292294.
  • 31
    Williams NP, Buchner LM, Shah DJ, Williams W. Adult T-cell leukemia/lymphoma in a renal transplant recipient: An opportunistic occurrence. Am J Nephrol 1994; 14: 226229.
  • 32
    Jenks PJ, Winsome BY, Raftery MJ et al. Development of human T-cell lymphotrophic virus type I-associated adult T-cell leukemia/lymphoma during immunosuppressive treatment following renal transplantation. Clin Infect Dis 1995; 21: 992993.
  • 33
    Hoshida Y, Li T, Dong Z et al. Lymphoproliferative disorders in renal transplant patients in Japan. Int J Cancer 2001; 91: 869875.DOI: 10.1002/1097-0215(200002)9999:9999<::AID-IJC1125>3.3.CO;2-E
  • 34
    Nakamura N, Arakaki Y, Sunagawa AH et al. Influence of immunosuppression in HTLV-1 – positive renal transplant recipients. Transplant Proc 1998; 30: 13241326.
  • 35
    Tanabe K, Kitani R, Takahashi K et al. Long-term results in human T-cell leukemia virus type 1-positive renal transplant recipients. Transplant Proc 1998; 30: 31683170.
  • 36
    Natazuka T, Umemiya-Okada T, Matsui T, Saida T, Nakao Y. FK506 and cyclosporine a regulate proliferation and proto-oncogene expression in HTLV-I-associated myelopathy/tropical-spastic-paraparesis-derived T cells. Int J Cancer 1993; 54: 348354.
  • 37
    Andrada-Serpa MJ, Schor D, Araujo AQ, Rumjanek VM. Immunological features of HTLV-I myelopathy in Rio de Janeiro, Brazil, and in vitro effects of cyclosporine A. J Neurol Sci 1996; 139: 714.
  • 38
    Kuroda Y, Takashima H, Yukitake M, Sakemi T. Development of HTLV-I-associated myelopathy after blood transfusion in a patient with aplastic anemia and a recipient of a renal transplant. J Neurol Sci 1992; 109: 196199.
  • 39
    Nakatsuji Y, Sugai F, Watanabe S et al. HTLV-I-associated myelopathy manifested after renal transplantation. J Neurol Sci 2000; 177: 154156.
  • 40
    Gout O, Baulac M, Gessain A et al. Rapid development of myelopathy after HTLV-I infection acquired by transfusion during cardiac transplantation. N Engl J Med 1990; 322: 383388.
  • 41
    Fretz C, Jaulmes D, Jordan G, Fournal JJ. HTLV-I transmission and myelopathy induced by blood transfusion. Transfusion 1991; 31: 379.
  • 42
    Panico M, Solomon M, Burrows L. Issues of informed consent and access to extended donor pool kidneys. Transplant Proc 1997; 29: 36673668.
  • 43
    Sells RA. Informed consent from recipients of marginal organ donors. Transplant Proc 1999; 31: 13241325.